Finch raises £43m to advance microbiome-based therapies for recurrent CDI, Autism and other disease areas

This article was originally published here

The financing comes from new investors including OCV Partners, Susquehanna International Group (SIG), Symbiosis LLC and the Trans-Pacific Technology Fund, as well as existing investors, including Avenir Growth

The post Finch raises £43m to advance microbiome-based therapies for recurrent CDI, Autism and other disease areas appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply